Shape matters: Biodegradable anisotropic nanoparticle artificial antigen presenting cells for cancer immunotherapy.

Animals Mice Antigen-Presenting Cells Lymphocyte Activation Immunotherapy / methods Melanoma / pathology Nanoparticles Antigens
Artificial antigen presenting cell Biomimetic Cancer Immunoengineering Nanoparticle shape

Journal

Acta biomaterialia
ISSN: 1878-7568
Titre abrégé: Acta Biomater
Pays: England
ID NLM: 101233144

Informations de publication

Date de publication:
01 04 2023
Historique:
received: 03 10 2022
revised: 31 01 2023
accepted: 14 02 2023
pmc-release: 01 04 2024
pubmed: 23 2 2023
medline: 21 3 2023
entrez: 22 2 2023
Statut: ppublish

Résumé

Artificial antigen presenting cells are biomimetic particles that recapitulate the signals presented by natural antigen presenting cells in order to stimulate T cells in an antigen-specific manner using an acellular platform. We have engineered an enhanced nanoscale biodegradable artificial antigen presenting cell by modulating particle shape to achieve a nanoparticle geometry that allows for increased radius of curvature and surface area for T cell contact. The non-spherical nanoparticle artificial antigen presenting cells developed here have reduced nonspecific uptake and improved circulation time compared both to spherical nanoparticles and to traditional microparticle technologies. Additionally, the anisotropic nanoparticle artificial antigen presenting cells efficiently engage with and activate T cells, ultimately leading to a marked anti-tumor effect in a mouse melanoma model that their spherical counterparts were unable to achieve. STATEMENT OF SIGNIFICANCE: Artificial antigen presenting cells (aAPC) can activate antigen-specific CD8+ T cells but have largely been limited to microparticle-based platforms and ex vivo T cell expansion. Although more amenable to in vivo use, nanoscale aAPC have traditionally been ineffective due to limited surface area available for T cell interaction. In this work, we engineered non-spherical biodegradable nanoscale aAPC to investigate the role of particle geometry and develop a translatable platform for T cell activation. The non-spherical aAPC developed here have increased surface area and a flatter surface for T cell engagement and, therefore, can more effectively stimulate antigen-specific T cells, resulting in anti-tumor efficacy in a mouse melanoma model.

Identifiants

DOI: 10.1016/j.actbio.2023.02.023 PMID: 36812956 PMC: PMC10335041
pubmed: 36812956
pii: S1742-7061(23)00106-X
doi: 10.1016/j.actbio.2023.02.023
pmc: PMC10335041
mid: NIHMS1877986
pii:
doi:

Substances chimiques

Antigens 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

187-197

Subventions

Organisme : NIBIB NIH HHS
ID : R01 EB029341
Pays : United States
Organisme : NCI NIH HHS
ID : R33 CA229042
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA108835
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA246699
Pays : United States
Organisme : NIBIB NIH HHS
ID : R21 EB023411
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA250367
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI044129
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB028239
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA153952
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA228133
Pays : United States

Informations de copyright

Copyright © 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Patents related to technology discussed in the manuscript have been filed by Johns Hopkins University with EBA, JWH, RAM, KRR, AKK, SYT, JPS, and JJG as co-inventors. Any potential conflicts of interest are managed by the Johns Hopkins University Committee on Outside Interests. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

ACS Omega. 2017 Mar 31;2(3):937-945
pubmed: 28393131
Trends Mol Med. 2005 Sep;11(9):412-20
pubmed: 16103011
ACS Nano. 2015 Jul 28;9(7):6861-71
pubmed: 26171764
J Immunol. 1992 Oct 1;149(7):2402-5
pubmed: 1527386
Sci Adv. 2020 Apr 15;6(16):eaay9035
pubmed: 32490199
Cancer Immunol Immunother. 2008 Feb;57(2):175-83
pubmed: 17657490
J Biol Chem. 2011 Oct 7;286(40):34883-92
pubmed: 21849500
J Immunol. 2004 Sep 1;173(5):3148-54
pubmed: 15322175
ACS Biomater Sci Eng. 2018 Mar 12;4(3):900-918
pubmed: 30555893
Small. 2015 Apr;11(13):1519-25
pubmed: 25641795
Nat Nanotechnol. 2020 Dec;15(12):963
pubmed: 33247210
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3270-5
pubmed: 23401509
J Immunol. 2005 Mar 15;174(6):3204-11
pubmed: 15749850
ACS Nano. 2014 Mar 25;8(3):2252-60
pubmed: 24564881
ACS Nano. 2022 Sep 27;16(9):15072-15085
pubmed: 35969506
Cancer Immunol Immunother. 2017 Sep;66(9):1229-1241
pubmed: 28501941
Trends Biotechnol. 2014 Apr;32(4):198-209
pubmed: 24630474
J Biomed Mater Res A. 2015 Aug;103(8):2747-57
pubmed: 25641799
Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4043-4052
pubmed: 32034097
Biomaterials. 2017 Feb;118:16-26
pubmed: 27940380
Nanomedicine. 2018 Feb;14(2):237-246
pubmed: 29127039
J Immunol Methods. 2001 Mar 1;249(1-2):111-9
pubmed: 11226469
Biomaterials. 2018 Dec;187:105-116
pubmed: 30312851
Biomaterials. 2014 Jan;35(1):269-277
pubmed: 24099710
Cancer Immunol Immunother. 2009 Feb;58(2):209-20
pubmed: 18563409
Nanomedicine. 2014 Jan;10(1):119-29
pubmed: 23891987
Sci Adv. 2020 Jun 10;6(24):eaba1474
pubmed: 32577517
Nat Nanotechnol. 2007 Apr;2(4):249-55
pubmed: 18654271
Biochem Biophys Res Commun. 2011 Aug 5;411(3):530-5
pubmed: 21756876
ACS Appl Mater Interfaces. 2021 Feb 24;13(7):7913-7923
pubmed: 33573372
Curr Protoc Immunol. 2001 May;Chapter 17:Unit 17.2
pubmed: 18432743
J Control Release. 2010 Nov 1;147(3):408-12
pubmed: 20691741
Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):4930-4
pubmed: 16549762
Adv Drug Deliv Rev. 2021 Oct;177:113807
pubmed: 34023331
Trends Biotechnol. 2014 Sep;32(9):456-65
pubmed: 24998519
Nat Med. 2003 May;9(5):619-24
pubmed: 12704385
Clin Immunol. 2003 Jan;106(1):16-22
pubmed: 12584046
J Immunol. 1997 Dec 15;159(12):5921-30
pubmed: 9550389
Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11901-4
pubmed: 17620615
Proc Natl Acad Sci U S A. 1978 Nov;75(11):5688-91
pubmed: 310125
J Vis Exp. 2018 Oct 12;(140):
pubmed: 30371668
Small. 2012 Jul 23;8(14):2222-30
pubmed: 22528663
Clin Cancer Res. 2009 Mar 1;15(5):1623-34
pubmed: 19208793
Mol Ther. 2008 Apr;16(4):765-72
pubmed: 18334990
Cancer Res. 2009 Dec 15;69(24):9376-84
pubmed: 19934317

Auteurs

Elana Ben-Akiva (E)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

John W Hickey (JW)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Randall A Meyer (RA)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Ariel Isser (A)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Sydney R Shannon (SR)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Natalie K Livingston (NK)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Kelly R Rhodes (KR)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Alyssa K Kosmides (AK)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Tiarra R Warren (TR)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Stephany Y Tzeng (SY)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Jonathan P Schneck (JP)

Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. Electronic address: jschnec1@jhmi.edu.

Jordan J Green (JJ)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for NanoBioTechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD 21231, USA; Department of Chemical & Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21231, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and the Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. Electronic address: green@jhu.edu.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Shape matters: Biodegradable anisotropic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Shape matters: Biodegradable anisotropic...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Cellules présentatrices d'antigène › Shape matters: Biodegradable anisotropic...
questionsmedicales.fr › Phénomènes du système immunitaire › Activation des lymphocytes › Shape matters: Biodegradable anisotropic...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Shape matters: Biodegradable anisotropic...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › Shape matters: Biodegradable anisotropic...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Shape matters: Biodegradable anisotropic...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Shape matters: Biodegradable anisotropic...